R
Ricard Solà
Researcher at Autonomous University of Barcelona
Publications - 168
Citations - 12594
Ricard Solà is an academic researcher from Autonomous University of Barcelona. The author has contributed to research in topics: Ribavirin & Hepatitis C. The author has an hindex of 40, co-authored 168 publications receiving 11284 citations.
Papers
More filters
Journal ArticleDOI
Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection
Richard K. Sterling,Eduardo Lissen,Eduardo Lissen,Nathan Clumeck,Ricard Solà,Mendes Cassia Correa,Julio S. G. Montaner,Mark S. Sulkowski,Francesca J. Torriani,Doug T. Dieterich,David L. Thomas,Diethelm Messinger,Mark T. Nelson +12 more
TL;DR: In conclusion, noninvasive tests can accurately predict hepatic fibrosis and may reduce the need for liver biopsy in the majority of HIV/HCV‐coinfected patients.
Journal ArticleDOI
Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial.
Josep M. Llovet,Maria Isabel Real,Xavier Montaña,Ramon Planas,Susana Coll,John J. Aponte,Carmen Ayuso,Margarita Sala,Jordi Muchart,Ricard Solà,Joan Rodés,Jordi Bruix +11 more
TL;DR: Chemoembolisation improved survival of stringently selected patients with unresectable hepatocellular carcinoma and was associated with a significantly lower rate of portal-vein invasion than conservative treatment.
Journal ArticleDOI
S-Adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial
José M. Mato,Javier Cámara,Javier Fernández de Paz,Llorenç Caballería,Susana Coll,Antonio Caballero,Luisa García-Buey,Joaquín Beltrán,Vicente Benita,Joan Caballería,Ricard Solà,Ricardo Moreno-Otero,Félix Barrao,Antonio Martín-Duce,Jose A Correa,Albert Parés,Elena Barrao,Inmaculada Garcı́a-Magaz,J. Puerta,Jorge Moreno,Gabrielle Boissard,Pablo Ortiz,Joan Rodés +22 more
TL;DR: It is indicated that long-term treatment with AdoMet may improve survival or delay liver transplantation in patients with alcoholic liver cirrhosis, especially in those with less advanced liver disease.
Journal ArticleDOI
Peginterferon-Alfa2a Plus Ribavirin for 48 Versus 72 Weeks in Patients With Detectable Hepatitis C Virus RNA at Week 4 of Treatment
José M. Sánchez Tapias,Moisés Diago,Escartin P,Jaime Enríquez,Manuel Romero Gomez,Rafael Bárcena,Javier Crespo,Raúl J. Andrade,Eva Martínez Bauer,Ramon Perez,M. Testillano,Ramon Planas,Ricard Solà,Manuel García Bengoechea,J. Samaniego,Miguel Muñoz–Sánchez,Ricardo Moreno–Otero +16 more
TL;DR: Extension of treatment with peginterferon-alfa2a plus ribavirin from 48 to 72 weeks significantly increases the rate of SVR in patients with detectable viremia at week 4 of treatment.
Journal ArticleDOI
Natural history of patients hospitalized for management of cirrhotic ascites.
Ramon Planas,Silvia Montoliu,Belén Ballesté,M. Rivera,Mireia Miquel,Helena Masnou,Jose Antonio Galeras,M.D. Giménez,Justiniano Santos,I. Cirera,Rosa Maria Morillas,Susanna Coll,Ricard Solà +12 more
TL;DR: The survival of cirrhotic patients with first episode of ascite is relatively high, and it is mainly influenced by age and Child-Pugh score at the time of ascites decompensation, as well as by DH development.